Teknova to Present Data on Novel Products to Accelerate the Development of AAV Therapies at ASGCT 2023 Annual Meeting
10 Maggio 2023 - 2:00PM
Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer
of critical reagents for the research, discovery, development, and
commercialization of novel therapies, vaccines, and molecular
diagnostics, today announced the Company’s upcoming presentations
at the American Society of Gene and Cell Therapy (ASGCT) 26th
Annual Meeting, where they will share data on novel products in
development that address critical pain points in AAV gene therapy
bioproduction.
Teknova’s Research and Development team will present three
posters over the course of the week-long event, being held at the
Los Angeles Convention Center from May 16-20, 2023. Each of the
posters and their associated data specifically focus on novel
products designed to streamline the end-to-end gene therapy process
development workflow and help the Company’s customers accelerate
their breakthroughs and get them into the clinic faster.
On Wednesday, May 17, 2023, at 12:00 p.m. Pacific Time, Teknova
will present data that proves the efficacy of the first product
released for sale in their new, proprietary product line, the
AAV-TekTM AEX Buffer Screening Kit. The poster, entitled Optimized
AEX Buffer Formulations for AAV Full Capsid Enrichment, will share
details on the extensive design of experiments (DOE) that the
Company conducted to determine the optimal equilibration and
elution buffer formulations that can save months in the AAV process
development timeline by effectively removing empty capsids while
maintaining maximum recovery and infectivity.
Teknova will also present two additional posters on Friday, May
19, 2023, at 12:00 p.m. Pacific Time: A novel AAV RNA-based
infectivity reporter assay, and Optimization of AAV sample
preparation towards accurate quantification of viral titer by
dPCR.
A novel AAV RNA-based infectivity reporter assay will present
the Company’s findings in using an RNA-sensing technology intended
to measure viral functional performance based on the gene of
interest. The infectivity reporter assay uses a novel method for
tagging an AAV transgene and results in the expression of a
fluorescent protein reporter upon transgene transcription.
Teknova’s data demonstrates that the assay can significantly
facilitate improvements in process development workflows for both
upstream and downstream optimization.
Optimization of AAV sample preparation towards accurate
quantification of viral titer by dPCR will share the Company’s
findings as they determined the best sample preparation for AAV
analysis by PCR-based methods to enable more accurate titer
measurements. Using a DOE approach, Teknova has successfully
established a select protocol for processing AAV samples prior to
dPCR.
For more information or to attend the ASGCT 26th Annual Meeting,
visit https://annualmeeting.asgct.org/.
For more information on Teknova’s products and services,
including their new AAV-Tek Solutions, visit www.teknova.com.
ABOUT
TEKNOVA Teknova makes
solutions possible. Since 1996, Teknova has been innovating the
manufacture of critical reagents for the life sciences industry to
accelerate the discovery and development of novel therapies that
will help people live longer, healthier lives. We offer fully
customizable solutions for every stage of the workflow, supporting
industry leaders in cell and gene therapy, molecular diagnostics,
and synthetic biology. Our fast turnaround of high-quality agar
plates, microbial culture media, buffers and reagents, and water
helps our customers scale seamlessly from RUO to GMP. Headquartered
in Hollister, California, with over 200,000 square feet of
state-of-the-art facilities, Teknova’s modular manufacturing
platform was designed by our team of scientists, engineers, and
quality control experts to efficiently produce the foundational
ingredients for the discovery and commercialization of novel
therapies.
Investor Contacts
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Sara Michelmore
MacDougall Advisors
smichelmore@macdougall.bio
+1 781-235-3060
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
Grafico Azioni Alpha Teknova (NASDAQ:TKNO)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Alpha Teknova (NASDAQ:TKNO)
Storico
Da Lug 2023 a Lug 2024